These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 36353535)

  • 1. Early monocyte response following local ablation in hepatocellular carcinoma.
    Kimm MA; Kästle S; Stechele MMR; Öcal E; Richter L; Ümütlü MR; Schinner R; Öcal O; Salvermoser L; Alunni-Fabbroni M; Seidensticker M; Goldberg SN; Ricke J; Wildgruber M
    Front Oncol; 2022; 12():959987. PubMed ID: 36353535
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Update on Percutaneous Local Ablative Procedures for the Treatment of Hepatocellular Carcinoma.
    Luerken L; Haimerl M; Doppler M; Uller W; Beyer LP; Stroszczynski C; Einspieler I
    Rofo; 2022 Oct; 194(10):1075-1086. PubMed ID: 35545102
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Efficacy and Therapeutic Outcome of Bipolar Radiofrequency Ablation for the Treatment for Hepatocellular Carcinoma in the Real-World Setting, Compared with Monopolar Radiofrequency Ablation Conducted during the Same Period.
    Tanaka T; Takata K; Kunimoto H; Fukuda H; Yamauchi R; Tsuchiya N; Inomata S; Yokoyama K; Morihara D; Takeyama Y; Shakado S; Sakisaka S; Hirai F
    Oncology; 2020; 98(12):859-868. PubMed ID: 32799203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Local ablation for hepatocellular carcinoma in taiwan.
    Lin SM
    Liver Cancer; 2013 Apr; 2(2):73-83. PubMed ID: 24159599
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic utility of systemic inflammatory markers and chronic hepatitis C virus infection status in hepatocellular carcinoma patients treated with local ablation.
    Ali MAM; Harmsen WS; Morsy KH; Galal GMK; Therneau TM; Roberts LR
    BMC Cancer; 2022 Feb; 22(1):221. PubMed ID: 35227234
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of radiofrequency ablation and ablative external radiotherapy for the treatment of intrahepatic malignancies: A hybrid meta-analysis.
    Rim CH; Lee JS; Kim SY; Seong J
    JHEP Rep; 2023 Jan; 5(1):100594. PubMed ID: 36561128
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of local ablative therapies, including radiofrequency ablation, microwave ablation, stereotactic ablative radiotherapy, and particle radiotherapy, for inoperable hepatocellular carcinoma: a systematic review and meta-analysis.
    Cheng PL; Wu PH; Kao WY; Lai YT; Hsu JC; Chiou JF; Wu MH; Lee HL
    Exp Hematol Oncol; 2023 Apr; 12(1):37. PubMed ID: 37046292
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Priming of Sorafenib Prior to Radiofrequency Ablation Does Not Increase Treatment Effect in Hepatocellular Carcinoma.
    Bockorny B; Bullock AJ; Abrams TA; Faintuch S; Alsop DC; Goldberg SN; Ahmed M; Miksad RA
    Dig Dis Sci; 2022 Jul; 67(7):3455-3463. PubMed ID: 34297268
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Small single perivascular hepatocellular carcinoma: comparisons of radiofrequency ablation and microwave ablation by using propensity score analysis.
    An C; Li WZ; Huang ZM; Yu XL; Han YZ; Liu FY; Wu SS; Yu J; Liang P; Huang J
    Eur Radiol; 2021 Jul; 31(7):4764-4773. PubMed ID: 33399908
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The current role of radiofrequency ablation in the management of hepatocellular carcinoma: a systematic review.
    Lau WY; Lai EC
    Ann Surg; 2009 Jan; 249(1):20-5. PubMed ID: 19106671
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integrated proteogenomic characterization reveals an imbalanced hepatocellular carcinoma microenvironment after incomplete radiofrequency ablation.
    Shi ZR; Duan YX; Cui F; Wu ZJ; Li MP; Song PP; Peng QL; Ye WT; Yin KL; Kang MQ; Yu YX; Yang J; Tang W; Liao R
    J Exp Clin Cancer Res; 2023 May; 42(1):133. PubMed ID: 37231509
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proton beam radiotherapy vs. radiofrequency ablation for recurrent hepatocellular carcinoma: A randomized phase III trial.
    Kim TH; Koh YH; Kim BH; Kim MJ; Lee JH; Park B; Park JW
    J Hepatol; 2021 Mar; 74(3):603-612. PubMed ID: 33031846
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparisons of Radiofrequency Ablation, Microwave Ablation, and Irreversible Electroporation by Using Propensity Score Analysis for Early Stage Hepatocellular Carcinoma.
    Wada T; Sugimoto K; Sakamaki K; Takahashi H; Kakegawa T; Tomita Y; Abe M; Yoshimasu Y; Takeuchi H; Itoi T
    Cancers (Basel); 2023 Jan; 15(3):. PubMed ID: 36765689
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhancement of tumor-associated antigen-specific T cell responses by radiofrequency ablation of hepatocellular carcinoma.
    Mizukoshi E; Yamashita T; Arai K; Sunagozaka H; Ueda T; Arihara F; Kagaya T; Yamashita T; Fushimi K; Kaneko S
    Hepatology; 2013 Apr; 57(4):1448-57. PubMed ID: 23174905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insufficient ablative margin determined by early computed tomography may predict the recurrence of hepatocellular carcinoma after radiofrequency ablation.
    Teng W; Liu KW; Lin CC; Jeng WJ; Chen WT; Sheen IS; Lin CY; Lin SM
    Liver Cancer; 2015 Mar; 4(1):26-38. PubMed ID: 26020027
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rate of local tumor progression following radiofrequency ablation of pathologically early hepatocellular carcinoma.
    Hao Y; Numata K; Ishii T; Fukuda H; Maeda S; Nakano M; Tanaka K
    World J Gastroenterol; 2017 May; 23(17):3111-3121. PubMed ID: 28533668
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term outcome of percutaneous radiofrequency ablation for periportal hepatocellular carcinoma: tumor recurrence or progression, survival and clinical significance.
    Cao S; Lyu T; Fan Z; Guan H; Song L; Tong X; Wang J; Zou Y
    Cancer Imaging; 2022 Jan; 22(1):2. PubMed ID: 34983650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Iodine-125 Brachytherapy Can Prolong Progression-Free Survival of Patients with Locoregional Recurrence and/or Residual Hepatocellular Carcinoma After Radiofrequency Ablation.
    Chen L; Ying X; Zhang D; Lai L; Wu F; Tu J; Ji J
    Cancer Biother Radiopharm; 2021 Dec; 36(10):820-826. PubMed ID: 32551979
    [No Abstract]   [Full Text] [Related]  

  • 19. Stereotactic body radiation therapy vs. radiofrequency ablation in Asian patients with hepatocellular carcinoma.
    Kim N; Cheng J; Jung I; Liang J; Shih YL; Huang WY; Kimura T; Lee VHF; Zeng ZC; Zhenggan R; Kay CS; Heo SJ; Won JY; Seong J
    J Hepatol; 2020 Jul; 73(1):121-129. PubMed ID: 32165253
    [TBL] [Abstract][Full Text] [Related]  

  • 20. No-touch multibipolar radiofrequency ablation vs. surgical resection for solitary hepatocellular carcinoma ranging from 2 to 5 cm.
    Mohkam K; Dumont PN; Manichon AF; Jouvet JC; Boussel L; Merle P; Ducerf C; Lesurtel M; Rode A; Mabrut JY
    J Hepatol; 2018 Jun; 68(6):1172-1180. PubMed ID: 29410287
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.